Krysztof Brzozka

Krysztof Brzozka

Company: Ryvu Therapeutics

Job title: Chief Scientific Officer & Executive Vice President

Seminars:

Speaker Q&A 3:40 pm

Read more

day: Day One

New Generation of STING Agonists – Development & Characterization of a Novel Series of Systemic Immunomodulators with Improved Potency 2:50 pm

New generation Ryvu STING agonists are strong binders of human STING protein and show high cellular potency of inducing cytokine production in human immune cells at low nM range The compounds are characterized by drug-like properties and high in vitro potency irrespective of the natural human STING variant and the chemotype is amenable for linking…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.